Dedicated to the

diagnosis and treatment

of hypercoagulable conditions

What we do

King's Thrombosis Centre First Registry image

Clinical Practice and Education

King's Thrombosis Centre - Exemplar Centre image

Patient information

King's Thrombosis Centre are proud to have been the primary exemplar centre within the VTE Network.

King's Thrombosis Centre - Research image


We are an experienced multi-disciplinary clinical academic team, conducting translational research in the field of thrombosis and haemostasis.


The King's Thrombosis Centre is a leading multidisciplinary clinical and research group dedicated to the diagnosis and treatment of hypercoagulable conditions.

We are a designated Haemophilia Centre and were the first National Venous Thromboembolism (VTE) Exemplar Centre, reflecting our national leadership in the prevention and treatment of VTE. Our clinical trials unit works in partnership with industry to develop new treatments for VTE prevention and treatment.

King's Thrombosis Centre - About Us image

Anticoagulation News Items

The records below have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

Study (n=9492 with anticoagulation-associated intracerebral haemorrhage & documented reversal intervention status) found early anticoagulation reversal improved survival (door-to-treatment time ≤60min reduced inpatient mortality [adjusted odds ratio 0.83, 95% CI 0.69-1.00]).

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

JAMA Neurology

MHRA is asking anyone with excessive bleeding due to DOAC to report it to Yellow Card scheme, after which they may be contacted for consent to provide further information & submit a blood sample to explore if they are at higher risk of excessive bleeding due to genetic makeup.

Medicines and Healthcare products Regulatory Agency

Evidence for the interaction between SSRIs and low-dose ASA was found to be weak. It is uncertain whether adding an SSRI to low-dose ASA increases the bleeding risk. Adding low-dose ASA to an SSRI may confer an increased bleeding risk but this is also uncertain.

British Journal of Clinical Pharmacology


Are you involved in #VTE prevention in #pregnancy & post-partum? Do you use the @RCObsGyn Green-top guidance 37a? If so, we would ❤️ to know your views. Please fill in this 5 minute survey
@bhwords @Sue_Pavord @NNMN1 @richardbuka @HaemSTAR_UK @BritSocHaem

13/ So, in conclusion, IMO, ANNEXA-I does not show clear evidence of clinical benefit but there is definite evidence of harm. The logical argument for hematoma expansion as an outcome is compelling but not validated.

1/ Right, ANNEXA-I has dropped. The 1st ever RCT of a reversal agent for DOACs. Randomised patients with intracranial hemorrhage to andexanet alfa or usual care. Stopped early as it met its primary endpoint.
There are A LOT of talking points - LET'S GO!

Load More
Scroll to Top